Table 3. Treatment of recurrent disease.
| Variables | N | Percentage | |
|---|---|---|---|
| Recurrent disease | 91 | 100 | |
| HR positive | 63 | 69.2 | |
| Visceral crisis | 14 | 15.3 | |
| Hormonal therapy | 46 | 50.5 | |
| Adjuvant | Metastatic | ||
| Tamoxifen | AI | 2 | |
| AI | Tamoxifen | 2 | |
| Tamoxifen | Tamoxifen | 25 | |
| AI | AI | 7 | |
| None | Tamoxifen Or AI | 10 | |
| Tamoxifen Or AI | None | 12 | |
| Systemic chemotherapy | 56 | 61.5 | |
| Adjuvant | Metastatic | ||
| Taxane | Taxane | 22 | |
| Taxane | Non taxane | 9 | |
| Non taxane | Taxane | 16 | |
| Non taxane | Non taxane | 9 | |
| Monotherapy | 34 | ||
| Capecitabine | 18 | ||
| Taxane | 12 | ||
| Gemicitabine | 4 | ||
| Combination therapy | 22 | ||
| Her2 enriched | 7 | 7.7 | |
| Adjuvant herceptin | 1 | ||
| Metastatic herceptin | 2 |